Status:
COMPLETED
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
Lead Sponsor:
Eli Lilly and Company
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The purposes of this study are to assess the efficacy, safety, and side effects among doses approved by the Food and Drug Administration and higher (not FDA approved) doses of olanzapine in patients w...
Eligibility Criteria
Inclusion
- You must be 18 to 60 years old
- You must have been diagnosed with schizophrenia or schizoaffective disorder
- You must be able to visit the doctor's office 8 times over a 9 week period
- You must agree to participate with all tests and examinations that are required for this study
Exclusion
- You are a woman and are pregnant or breastfeeding
- You presently have an acute or unstable medical illness
- You have a history of an allergic reaction to olanzapine
- You are taking medications that are not permitted in this study. Your physician will discuss these with you
- You have taken part in another clinical research trial within the last 30 days or you have received treatment with a drug in the last 30 days that has not received regulatory approval.
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00100776
Start Date
September 1 2003
End Date
November 1 2005
Last Update
January 26 2007
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician
Anaheim, California, United States
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
National City, California, United States
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Orange, California, United States
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Pasadena, California, United States